NRC Health Segment Expenditure Addition To Long Lived Assets
NRC Health (NRC) reported Segment Expenditure Addition To Long Lived Assets of $1.28 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2025-11-07
- NRC Health segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $1.28M, a 87.25% decline year-over-year.
- NRC Health segment expenditure addition to long lived assets for the quarter ending 2025-06-30 was $3.53M, a 28.56% decline year-over-year.
- NRC Health segment expenditure addition to long lived assets for the quarter ending 2025-03-31 was $3.57M, a 24.70% decline year-over-year.
- NRC Health segment expenditure addition to long lived assets for the quarter ending 2024-12-31 was $3.40M.
- NRC Health segment expenditure addition to long lived assets for fiscal 2024 was $21.86M, a 16.83% increase from fiscal 2023.
- NRC Health segment expenditure addition to long lived assets for fiscal 2023 was $18.71M, a 87.73% increase from fiscal 2022.
- NRC Health segment expenditure addition to long lived assets for fiscal 2022 was $9.96M.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.28M 10-Q · filed 2025-11-07 | $4.81M derived: sum of 2 quarters · filed 2025-11-07 | $8.37M 10-Q · filed 2025-11-07 | $11.77M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | $3.53M 10-Q · filed 2025-08-08 | $7.09M 10-Q · filed 2025-08-08 | $10.49M derived: sum of 3 quarters · filed 2025-08-08 | $20.52M derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-03-31 | $3.57M 10-Q · filed 2025-05-09 | $6.96M derived: sum of 2 quarters · filed 2025-05-09 | $17.00M derived: sum of 3 quarters · filed 2025-11-07 | $21.94M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $13.43M derived: sum of 2 quarters · filed 2025-11-07 | $18.37M derived: sum of 3 quarters · filed 2025-11-07 | $21.86M 10-K · filed 2025-03-17 |
| 2024-09-30 | $10.03M 10-Q · filed 2025-11-07 | $14.97M derived: sum of 2 quarters · filed 2025-11-07 | $18.46M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $4.94M 10-Q · filed 2025-08-08 | $8.43M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $4.74M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $18.71M 10-K · filed 2025-03-17 | |||
| 2022-12-31 | $9.96M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |